单位：[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China华中科技大学同济医学院附属同济医院肿瘤科
In recent years, immune checkpoint inhibitors (ICIs) have become an important treatment strategy for advanced gastric cancer. Immunotherapy has gradually transitioned from a later-line to a first-line treatment for advanced gastric cancer. Simultaneously, more and more researchers have begun to pay attention to whether immunotherapy can be used for resectable gastric cancer. The current use of ICIs in the neoadjuvant treatment of gastric cancer is still in its exploratory stage, with a number of clinical trials currently underway. However, the available data show good application prospects. This article reviewsthe research progress on ICIs in the neoadjuvant therapy for gastric cancer and evokes some unresolved problems.
语种：
外文
第一作者：
推荐引用方式(GB/T 7714)：
Wenting Li,Shiying Yu.Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer[J].Oncology and Translational Medicine.2022,(2):doi:10.1007/s10330-022-0551-1.
APA：
Wenting Li&Shiying Yu.(2022).Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer.Oncology and Translational Medicine,,(2)
MLA：
Wenting Li,et al."Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer".Oncology and Translational Medicine ..2(2022)
